nodes	percent_of_prediction	percent_of_DWPC	metapath
Alitretinoin—hematologic cancer—muscle cancer	0.51	0.65	CtDrD
Alitretinoin—peripheral nervous system neoplasm—muscle cancer	0.274	0.35	CtDrD
Alitretinoin—CYP1A2—Dacarbazine—muscle cancer	0.0201	0.269	CbGbCtD
Alitretinoin—ABCB1—Dactinomycin—muscle cancer	0.0152	0.204	CbGbCtD
Alitretinoin—CYP1A2—Etoposide—muscle cancer	0.00982	0.132	CbGbCtD
Alitretinoin—ABCB1—Vincristine—muscle cancer	0.00937	0.126	CbGbCtD
Alitretinoin—ABCB1—Etoposide—muscle cancer	0.00859	0.115	CbGbCtD
Alitretinoin—ABCB1—Doxorubicin—muscle cancer	0.00586	0.0785	CbGbCtD
Alitretinoin—ABCB1—Methotrexate—muscle cancer	0.00568	0.0761	CbGbCtD
Alitretinoin—CRABP1—Pyruvate metabolism and Citric Acid (TCA) cycle—FH—muscle cancer	0.00249	0.131	CbGpPWpGaD
Alitretinoin—CRABP2—Pyruvate metabolism and Citric Acid (TCA) cycle—FH—muscle cancer	0.00249	0.131	CbGpPWpGaD
Alitretinoin—CRABP1—embryo—muscle cancer	0.00206	0.0612	CbGeAlD
Alitretinoin—CRABP2—embryo—muscle cancer	0.00186	0.0553	CbGeAlD
Alitretinoin—CRABP2—smooth muscle tissue—muscle cancer	0.00147	0.0435	CbGeAlD
Alitretinoin—RXRA—renal system—muscle cancer	0.0014	0.0417	CbGeAlD
Alitretinoin—CRABP1—tendon—muscle cancer	0.00122	0.0362	CbGeAlD
Alitretinoin—CRABP1—vagina—muscle cancer	0.00113	0.0336	CbGeAlD
Alitretinoin—CRABP2—tendon—muscle cancer	0.0011	0.0327	CbGeAlD
Alitretinoin—CRABP1—head—muscle cancer	0.00104	0.031	CbGeAlD
Alitretinoin—RXRB—cardiac atrium—muscle cancer	0.00104	0.0308	CbGeAlD
Alitretinoin—CRABP2—vagina—muscle cancer	0.00102	0.0303	CbGeAlD
Alitretinoin—CRABP1—testis—muscle cancer	0.00101	0.0299	CbGeAlD
Alitretinoin—RARB—tendon—muscle cancer	0.000985	0.0292	CbGeAlD
Alitretinoin—RARA—renal system—muscle cancer	0.000968	0.0287	CbGeAlD
Alitretinoin—CRABP1—The citric acid (TCA) cycle and respiratory electron transport—FH—muscle cancer	0.000966	0.0508	CbGpPWpGaD
Alitretinoin—CRABP2—The citric acid (TCA) cycle and respiratory electron transport—FH—muscle cancer	0.000966	0.0508	CbGpPWpGaD
Alitretinoin—RXRG—tendon—muscle cancer	0.000963	0.0286	CbGeAlD
Alitretinoin—CRABP2—head—muscle cancer	0.000944	0.028	CbGeAlD
Alitretinoin—RXRA—head—muscle cancer	0.00094	0.0279	CbGeAlD
Alitretinoin—RARB—vagina—muscle cancer	0.000914	0.0271	CbGeAlD
Alitretinoin—CRABP2—testis—muscle cancer	0.000912	0.0271	CbGeAlD
Alitretinoin—RXRB—tendon—muscle cancer	0.000905	0.0269	CbGeAlD
Alitretinoin—RARB—head—muscle cancer	0.000844	0.0251	CbGeAlD
Alitretinoin—RXRB—vagina—muscle cancer	0.00084	0.0249	CbGeAlD
Alitretinoin—RXRG—head—muscle cancer	0.000825	0.0245	CbGeAlD
Alitretinoin—RARG—tendon—muscle cancer	0.000803	0.0239	CbGeAlD
Alitretinoin—RXRG—testis—muscle cancer	0.000797	0.0237	CbGeAlD
Alitretinoin—RXRB—head—muscle cancer	0.000776	0.023	CbGeAlD
Alitretinoin—RARA—tendon—muscle cancer	0.000755	0.0224	CbGeAlD
Alitretinoin—RXRA—Pyruvate metabolism and Citric Acid (TCA) cycle—FH—muscle cancer	0.000754	0.0397	CbGpPWpGaD
Alitretinoin—RXRB—testis—muscle cancer	0.000749	0.0223	CbGeAlD
Alitretinoin—RARG—vagina—muscle cancer	0.000745	0.0221	CbGeAlD
Alitretinoin—RARA—bone marrow—muscle cancer	0.000732	0.0217	CbGeAlD
Alitretinoin—RARG—head—muscle cancer	0.000689	0.0204	CbGeAlD
Alitretinoin—RARG—testis—muscle cancer	0.000665	0.0198	CbGeAlD
Alitretinoin—RARA—head—muscle cancer	0.000647	0.0192	CbGeAlD
Alitretinoin—RARA—testis—muscle cancer	0.000625	0.0186	CbGeAlD
Alitretinoin—CRABP2—Fatty acid, triacylglycerol, and ketone body metabolism—MED12—muscle cancer	0.000464	0.0244	CbGpPWpGaD
Alitretinoin—CRABP1—Fatty acid, triacylglycerol, and ketone body metabolism—MED12—muscle cancer	0.000464	0.0244	CbGpPWpGaD
Alitretinoin—RXRG—Regulation of Androgen receptor activity—FOXO1—muscle cancer	0.000419	0.022	CbGpPWpGaD
Alitretinoin—RXRA—Transcription factor regulation in adipogenesis—FOXO1—muscle cancer	0.000415	0.0218	CbGpPWpGaD
Alitretinoin—RXRB—Regulation of Androgen receptor activity—FOXO1—muscle cancer	0.000394	0.0207	CbGpPWpGaD
Alitretinoin—CYP1A2—renal system—muscle cancer	0.000359	0.0107	CbGeAlD
Alitretinoin—RXRG—Adipogenesis—HMGA1—muscle cancer	0.000308	0.0162	CbGpPWpGaD
Alitretinoin—RXRA—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000307	0.0162	CbGpPWpGaD
Alitretinoin—RXRA—The citric acid (TCA) cycle and respiratory electron transport—FH—muscle cancer	0.000293	0.0154	CbGpPWpGaD
Alitretinoin—RARA—Adipogenesis—HMGA1—muscle cancer	0.00029	0.0153	CbGpPWpGaD
Alitretinoin—RXRA—Transcriptional regulation of white adipocyte differentiation—MED12—muscle cancer	0.000277	0.0146	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.000273	0.0143	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.000261	0.0138	CbGpPWpGaD
Alitretinoin—RXRG—Regulation of Androgen receptor activity—MDM2—muscle cancer	0.000251	0.0132	CbGpPWpGaD
Alitretinoin—ABCB1—embryo—muscle cancer	0.000243	0.00721	CbGeAlD
Alitretinoin—RXRB—Regulation of Androgen receptor activity—MDM2—muscle cancer	0.000236	0.0124	CbGpPWpGaD
Alitretinoin—RXRA—PPARA activates gene expression—MED12—muscle cancer	0.000208	0.011	CbGpPWpGaD
Alitretinoin—RXRA—Regulation of Androgen receptor activity—FOXO1—muscle cancer	0.000205	0.0108	CbGpPWpGaD
Alitretinoin—RXRG—Adipogenesis—FOXO1—muscle cancer	0.000204	0.0107	CbGpPWpGaD
Alitretinoin—RXRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—MED12—muscle cancer	0.000204	0.0107	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.000199	0.0105	CbGpPWpGaD
Alitretinoin—RARA—Adipogenesis—FOXO1—muscle cancer	0.000192	0.0101	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.000191	0.0101	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.000185	0.00973	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.000185	0.00973	CbGpPWpGaD
Alitretinoin—ABCB1—renal system—muscle cancer	0.000184	0.00546	CbGeAlD
Alitretinoin—RXRA—Developmental Biology—MYF5—muscle cancer	0.000172	0.00906	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—MYF6—muscle cancer	0.000172	0.00906	CbGpPWpGaD
Alitretinoin—RXRA—Adipogenesis—HMGA1—muscle cancer	0.000151	0.00795	CbGpPWpGaD
Alitretinoin—RARG—Generic Transcription Pathway—MED12—muscle cancer	0.000149	0.00782	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—FH—muscle cancer	0.000146	0.00767	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—FH—muscle cancer	0.000146	0.00767	CbGpPWpGaD
Alitretinoin—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—MED12—muscle cancer	0.000141	0.0074	CbGpPWpGaD
Alitretinoin—ABCB1—bone marrow—muscle cancer	0.000139	0.00413	CbGeAlD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.000136	0.00717	CbGpPWpGaD
Alitretinoin—RXRG—Generic Transcription Pathway—MED12—muscle cancer	0.000136	0.00715	CbGpPWpGaD
Alitretinoin—RARB—Generic Transcription Pathway—MED12—muscle cancer	0.000133	0.00701	CbGpPWpGaD
Alitretinoin—ABCB1—vagina—muscle cancer	0.000133	0.00395	CbGeAlD
Alitretinoin—RARA—Generic Transcription Pathway—MED12—muscle cancer	0.000128	0.00672	CbGpPWpGaD
Alitretinoin—RXRB—Generic Transcription Pathway—MED12—muscle cancer	0.000128	0.00672	CbGpPWpGaD
Alitretinoin—RXRA—Regulation of Androgen receptor activity—MDM2—muscle cancer	0.000123	0.00648	CbGpPWpGaD
Alitretinoin—ABCB1—head—muscle cancer	0.000123	0.00365	CbGeAlD
Alitretinoin—ABCB1—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000123	0.00646	CbGpPWpGaD
Alitretinoin—ABCB1—testis—muscle cancer	0.000119	0.00353	CbGeAlD
Alitretinoin—RXRA—Developmental Biology—MYOG—muscle cancer	0.000111	0.00584	CbGpPWpGaD
Alitretinoin—CYP1A2—Melatonin metabolism and effects—FOXO1—muscle cancer	0.000106	0.00558	CbGpPWpGaD
Alitretinoin—RXRA—Adipogenesis—FOXO1—muscle cancer	0.0001	0.00527	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	9.96e-05	0.00524	CbGpPWpGaD
Alitretinoin—Chest pain—Etoposide—muscle cancer	8.85e-05	0.000998	CcSEcCtD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	8.84e-05	0.00465	CbGpPWpGaD
Alitretinoin—Affect lability—Doxorubicin—muscle cancer	8.81e-05	0.000994	CcSEcCtD
Alitretinoin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	8.79e-05	0.000991	CcSEcCtD
Alitretinoin—Pancreatitis—Methotrexate—muscle cancer	8.76e-05	0.000988	CcSEcCtD
Alitretinoin—Discomfort—Etoposide—muscle cancer	8.74e-05	0.000986	CcSEcCtD
Alitretinoin—Face oedema—Doxorubicin—muscle cancer	8.64e-05	0.000975	CcSEcCtD
Alitretinoin—Hypersensitivity—Dactinomycin—muscle cancer	8.63e-05	0.000974	CcSEcCtD
Alitretinoin—Abdominal discomfort—Methotrexate—muscle cancer	8.56e-05	0.000966	CcSEcCtD
Alitretinoin—Gastrointestinal pain—Vincristine—muscle cancer	8.56e-05	0.000966	CcSEcCtD
Alitretinoin—Confusional state—Etoposide—muscle cancer	8.55e-05	0.000965	CcSEcCtD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	8.52e-05	0.00448	CbGpPWpGaD
Alitretinoin—Cardiac arrest—Doxorubicin—muscle cancer	8.51e-05	0.00096	CcSEcCtD
Alitretinoin—Anaphylactic shock—Etoposide—muscle cancer	8.48e-05	0.000957	CcSEcCtD
Alitretinoin—Mood swings—Doxorubicin—muscle cancer	8.48e-05	0.000956	CcSEcCtD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	8.47e-05	0.00446	CbGpPWpGaD
Alitretinoin—Infection—Etoposide—muscle cancer	8.43e-05	0.000951	CcSEcCtD
Alitretinoin—Asthenia—Dactinomycin—muscle cancer	8.41e-05	0.000948	CcSEcCtD
Alitretinoin—Blood creatinine increased—Doxorubicin—muscle cancer	8.38e-05	0.000946	CcSEcCtD
Alitretinoin—Neutropenia—Methotrexate—muscle cancer	8.35e-05	0.000942	CcSEcCtD
Alitretinoin—Dysuria—Methotrexate—muscle cancer	8.35e-05	0.000942	CcSEcCtD
Alitretinoin—Dehydration—Doxorubicin—muscle cancer	8.32e-05	0.000939	CcSEcCtD
Alitretinoin—Thrombocytopenia—Etoposide—muscle cancer	8.3e-05	0.000937	CcSEcCtD
Alitretinoin—Upper respiratory tract infection—Methotrexate—muscle cancer	8.3e-05	0.000937	CcSEcCtD
Alitretinoin—Tachycardia—Etoposide—muscle cancer	8.28e-05	0.000934	CcSEcCtD
Alitretinoin—Abdominal pain—Vincristine—muscle cancer	8.28e-05	0.000934	CcSEcCtD
Alitretinoin—Body temperature increased—Vincristine—muscle cancer	8.28e-05	0.000934	CcSEcCtD
Alitretinoin—Skin disorder—Etoposide—muscle cancer	8.24e-05	0.000929	CcSEcCtD
Alitretinoin—CRABP1—Metabolism—MED12—muscle cancer	8.23e-05	0.00433	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—MED12—muscle cancer	8.23e-05	0.00433	CbGpPWpGaD
Alitretinoin—Dry skin—Doxorubicin—muscle cancer	8.2e-05	0.000925	CcSEcCtD
Alitretinoin—Hyperhidrosis—Etoposide—muscle cancer	8.2e-05	0.000925	CcSEcCtD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	8.17e-05	0.0043	CbGpPWpGaD
Alitretinoin—Photosensitivity reaction—Methotrexate—muscle cancer	8.15e-05	0.00092	CcSEcCtD
Alitretinoin—Anorexia—Etoposide—muscle cancer	8.08e-05	0.000912	CcSEcCtD
Alitretinoin—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	8.06e-05	0.000909	CcSEcCtD
Alitretinoin—Diarrhoea—Dactinomycin—muscle cancer	8.02e-05	0.000905	CcSEcCtD
Alitretinoin—Pneumonia—Methotrexate—muscle cancer	8.01e-05	0.000904	CcSEcCtD
Alitretinoin—Nasopharyngitis—Doxorubicin—muscle cancer	8e-05	0.000903	CcSEcCtD
Alitretinoin—Infestation NOS—Methotrexate—muscle cancer	7.97e-05	0.000899	CcSEcCtD
Alitretinoin—Drowsiness—Methotrexate—muscle cancer	7.97e-05	0.000899	CcSEcCtD
Alitretinoin—Infestation—Methotrexate—muscle cancer	7.97e-05	0.000899	CcSEcCtD
Alitretinoin—Depression—Methotrexate—muscle cancer	7.94e-05	0.000896	CcSEcCtD
Alitretinoin—Hypotension—Etoposide—muscle cancer	7.93e-05	0.000894	CcSEcCtD
Alitretinoin—Gastritis—Doxorubicin—muscle cancer	7.92e-05	0.000894	CcSEcCtD
Alitretinoin—Stevens-Johnson syndrome—Methotrexate—muscle cancer	7.9e-05	0.000891	CcSEcCtD
Alitretinoin—Renal failure—Methotrexate—muscle cancer	7.83e-05	0.000883	CcSEcCtD
Alitretinoin—Abdominal distension—Doxorubicin—muscle cancer	7.79e-05	0.000879	CcSEcCtD
Alitretinoin—Stomatitis—Methotrexate—muscle cancer	7.76e-05	0.000876	CcSEcCtD
Alitretinoin—Conjunctivitis—Methotrexate—muscle cancer	7.74e-05	0.000873	CcSEcCtD
Alitretinoin—Dysphagia—Doxorubicin—muscle cancer	7.74e-05	0.000873	CcSEcCtD
Alitretinoin—Asthma—Doxorubicin—muscle cancer	7.74e-05	0.000873	CcSEcCtD
Alitretinoin—Hypersensitivity—Vincristine—muscle cancer	7.71e-05	0.00087	CcSEcCtD
Alitretinoin—Sweating—Methotrexate—muscle cancer	7.64e-05	0.000861	CcSEcCtD
Alitretinoin—Paraesthesia—Etoposide—muscle cancer	7.62e-05	0.000859	CcSEcCtD
Alitretinoin—Haematuria—Methotrexate—muscle cancer	7.59e-05	0.000857	CcSEcCtD
Alitretinoin—Pancreatitis—Doxorubicin—muscle cancer	7.58e-05	0.000856	CcSEcCtD
Alitretinoin—Dyspnoea—Etoposide—muscle cancer	7.56e-05	0.000853	CcSEcCtD
Alitretinoin—Somnolence—Etoposide—muscle cancer	7.54e-05	0.000851	CcSEcCtD
Alitretinoin—Epistaxis—Methotrexate—muscle cancer	7.51e-05	0.000848	CcSEcCtD
Alitretinoin—Asthenia—Vincristine—muscle cancer	7.51e-05	0.000847	CcSEcCtD
Alitretinoin—CRABP2—Metabolism—ENO2—muscle cancer	7.51e-05	0.00395	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—ENO2—muscle cancer	7.51e-05	0.00395	CbGpPWpGaD
Alitretinoin—Vomiting—Dactinomycin—muscle cancer	7.45e-05	0.000841	CcSEcCtD
Alitretinoin—Agranulocytosis—Methotrexate—muscle cancer	7.43e-05	0.000839	CcSEcCtD
Alitretinoin—Rash—Dactinomycin—muscle cancer	7.39e-05	0.000834	CcSEcCtD
Alitretinoin—Decreased appetite—Etoposide—muscle cancer	7.37e-05	0.000832	CcSEcCtD
Alitretinoin—Gastrointestinal disorder—Etoposide—muscle cancer	7.32e-05	0.000826	CcSEcCtD
Alitretinoin—Fatigue—Etoposide—muscle cancer	7.31e-05	0.000825	CcSEcCtD
Alitretinoin—Constipation—Etoposide—muscle cancer	7.25e-05	0.000818	CcSEcCtD
Alitretinoin—Pain—Etoposide—muscle cancer	7.25e-05	0.000818	CcSEcCtD
Alitretinoin—Neutropenia—Doxorubicin—muscle cancer	7.23e-05	0.000816	CcSEcCtD
Alitretinoin—Dysuria—Doxorubicin—muscle cancer	7.23e-05	0.000816	CcSEcCtD
Alitretinoin—Upper respiratory tract infection—Doxorubicin—muscle cancer	7.19e-05	0.000811	CcSEcCtD
Alitretinoin—Haemoglobin—Methotrexate—muscle cancer	7.19e-05	0.000811	CcSEcCtD
Alitretinoin—Diarrhoea—Vincristine—muscle cancer	7.16e-05	0.000808	CcSEcCtD
Alitretinoin—RARG—Gene Expression—MED12—muscle cancer	7.15e-05	0.00376	CbGpPWpGaD
Alitretinoin—Haemorrhage—Methotrexate—muscle cancer	7.15e-05	0.000807	CcSEcCtD
Alitretinoin—Hepatitis—Methotrexate—muscle cancer	7.15e-05	0.000807	CcSEcCtD
Alitretinoin—Pollakiuria—Doxorubicin—muscle cancer	7.15e-05	0.000806	CcSEcCtD
Alitretinoin—Pharyngitis—Methotrexate—muscle cancer	7.1e-05	0.000801	CcSEcCtD
Alitretinoin—Urinary tract disorder—Methotrexate—muscle cancer	7.06e-05	0.000797	CcSEcCtD
Alitretinoin—Photosensitivity reaction—Doxorubicin—muscle cancer	7.06e-05	0.000797	CcSEcCtD
Alitretinoin—Weight increased—Doxorubicin—muscle cancer	7.04e-05	0.000794	CcSEcCtD
Alitretinoin—Urethral disorder—Methotrexate—muscle cancer	7.01e-05	0.000791	CcSEcCtD
Alitretinoin—Weight decreased—Doxorubicin—muscle cancer	7e-05	0.000789	CcSEcCtD
Alitretinoin—Feeling abnormal—Etoposide—muscle cancer	6.99e-05	0.000788	CcSEcCtD
Alitretinoin—Nausea—Dactinomycin—muscle cancer	6.96e-05	0.000785	CcSEcCtD
Alitretinoin—Pneumonia—Doxorubicin—muscle cancer	6.94e-05	0.000783	CcSEcCtD
Alitretinoin—Gastrointestinal pain—Etoposide—muscle cancer	6.94e-05	0.000782	CcSEcCtD
Alitretinoin—Dizziness—Vincristine—muscle cancer	6.92e-05	0.000781	CcSEcCtD
Alitretinoin—Infestation—Doxorubicin—muscle cancer	6.9e-05	0.000778	CcSEcCtD
Alitretinoin—Infestation NOS—Doxorubicin—muscle cancer	6.9e-05	0.000778	CcSEcCtD
Alitretinoin—Drowsiness—Doxorubicin—muscle cancer	6.9e-05	0.000778	CcSEcCtD
Alitretinoin—Visual impairment—Methotrexate—muscle cancer	6.89e-05	0.000777	CcSEcCtD
Alitretinoin—RXRA—Developmental Biology—MYOD1—muscle cancer	6.85e-05	0.00361	CbGpPWpGaD
Alitretinoin—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	6.84e-05	0.000771	CcSEcCtD
Alitretinoin—Renal failure—Doxorubicin—muscle cancer	6.78e-05	0.000765	CcSEcCtD
Alitretinoin—Erythema multiforme—Methotrexate—muscle cancer	6.76e-05	0.000763	CcSEcCtD
Alitretinoin—Neuropathy peripheral—Doxorubicin—muscle cancer	6.76e-05	0.000763	CcSEcCtD
Alitretinoin—Urticaria—Etoposide—muscle cancer	6.74e-05	0.00076	CcSEcCtD
Alitretinoin—Stomatitis—Doxorubicin—muscle cancer	6.72e-05	0.000758	CcSEcCtD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	6.71e-05	0.00353	CbGpPWpGaD
Alitretinoin—Abdominal pain—Etoposide—muscle cancer	6.7e-05	0.000756	CcSEcCtD
Alitretinoin—Body temperature increased—Etoposide—muscle cancer	6.7e-05	0.000756	CcSEcCtD
Alitretinoin—Urinary tract infection—Doxorubicin—muscle cancer	6.7e-05	0.000756	CcSEcCtD
Alitretinoin—Conjunctivitis—Doxorubicin—muscle cancer	6.7e-05	0.000756	CcSEcCtD
Alitretinoin—Eye disorder—Methotrexate—muscle cancer	6.68e-05	0.000754	CcSEcCtD
Alitretinoin—Tinnitus—Methotrexate—muscle cancer	6.67e-05	0.000752	CcSEcCtD
Alitretinoin—RXRA—Generic Transcription Pathway—MED12—muscle cancer	6.66e-05	0.0035	CbGpPWpGaD
Alitretinoin—Vomiting—Vincristine—muscle cancer	6.66e-05	0.000751	CcSEcCtD
Alitretinoin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—muscle cancer	6.65e-05	0.0035	CbGpPWpGaD
Alitretinoin—Sweating—Doxorubicin—muscle cancer	6.61e-05	0.000746	CcSEcCtD
Alitretinoin—Rash—Vincristine—muscle cancer	6.6e-05	0.000745	CcSEcCtD
Alitretinoin—Dermatitis—Vincristine—muscle cancer	6.6e-05	0.000744	CcSEcCtD
Alitretinoin—Haematuria—Doxorubicin—muscle cancer	6.58e-05	0.000742	CcSEcCtD
Alitretinoin—Headache—Vincristine—muscle cancer	6.56e-05	0.00074	CcSEcCtD
Alitretinoin—RXRG—Gene Expression—MED12—muscle cancer	6.54e-05	0.00344	CbGpPWpGaD
Alitretinoin—Epistaxis—Doxorubicin—muscle cancer	6.51e-05	0.000734	CcSEcCtD
Alitretinoin—Angiopathy—Methotrexate—muscle cancer	6.49e-05	0.000732	CcSEcCtD
Alitretinoin—Sinusitis—Doxorubicin—muscle cancer	6.47e-05	0.00073	CcSEcCtD
Alitretinoin—Agranulocytosis—Doxorubicin—muscle cancer	6.44e-05	0.000726	CcSEcCtD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	6.43e-05	0.00339	CbGpPWpGaD
Alitretinoin—RARB—Gene Expression—MED12—muscle cancer	6.42e-05	0.00338	CbGpPWpGaD
Alitretinoin—Chills—Methotrexate—muscle cancer	6.42e-05	0.000724	CcSEcCtD
Alitretinoin—Alopecia—Methotrexate—muscle cancer	6.32e-05	0.000713	CcSEcCtD
Alitretinoin—RXRA—Developmental Biology—MED12—muscle cancer	6.27e-05	0.0033	CbGpPWpGaD
Alitretinoin—Mental disorder—Methotrexate—muscle cancer	6.26e-05	0.000707	CcSEcCtD
Alitretinoin—Hypersensitivity—Etoposide—muscle cancer	6.25e-05	0.000705	CcSEcCtD
Alitretinoin—Malnutrition—Methotrexate—muscle cancer	6.22e-05	0.000702	CcSEcCtD
Alitretinoin—Erythema—Methotrexate—muscle cancer	6.22e-05	0.000702	CcSEcCtD
Alitretinoin—Haemoglobin—Doxorubicin—muscle cancer	6.22e-05	0.000702	CcSEcCtD
Alitretinoin—Nausea—Vincristine—muscle cancer	6.22e-05	0.000702	CcSEcCtD
Alitretinoin—Haemorrhage—Doxorubicin—muscle cancer	6.19e-05	0.000698	CcSEcCtD
Alitretinoin—Hepatitis—Doxorubicin—muscle cancer	6.19e-05	0.000698	CcSEcCtD
Alitretinoin—Hypoaesthesia—Doxorubicin—muscle cancer	6.16e-05	0.000695	CcSEcCtD
Alitretinoin—RARA—Gene Expression—MED12—muscle cancer	6.15e-05	0.00324	CbGpPWpGaD
Alitretinoin—RXRB—Gene Expression—MED12—muscle cancer	6.15e-05	0.00324	CbGpPWpGaD
Alitretinoin—Pharyngitis—Doxorubicin—muscle cancer	6.15e-05	0.000693	CcSEcCtD
Alitretinoin—Urinary tract disorder—Doxorubicin—muscle cancer	6.11e-05	0.00069	CcSEcCtD
Alitretinoin—Oedema peripheral—Doxorubicin—muscle cancer	6.1e-05	0.000688	CcSEcCtD
Alitretinoin—Asthenia—Etoposide—muscle cancer	6.09e-05	0.000686	CcSEcCtD
Alitretinoin—Urethral disorder—Doxorubicin—muscle cancer	6.07e-05	0.000685	CcSEcCtD
Alitretinoin—Back pain—Methotrexate—muscle cancer	6.02e-05	0.000679	CcSEcCtD
Alitretinoin—Pruritus—Etoposide—muscle cancer	6e-05	0.000677	CcSEcCtD
Alitretinoin—Visual impairment—Doxorubicin—muscle cancer	5.97e-05	0.000673	CcSEcCtD
Alitretinoin—CRABP1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	5.87e-05	0.00309	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	5.87e-05	0.00309	CbGpPWpGaD
Alitretinoin—Vision blurred—Methotrexate—muscle cancer	5.87e-05	0.000662	CcSEcCtD
Alitretinoin—Erythema multiforme—Doxorubicin—muscle cancer	5.85e-05	0.00066	CcSEcCtD
Alitretinoin—Diarrhoea—Etoposide—muscle cancer	5.8e-05	0.000655	CcSEcCtD
Alitretinoin—Eye disorder—Doxorubicin—muscle cancer	5.79e-05	0.000653	CcSEcCtD
Alitretinoin—Ill-defined disorder—Methotrexate—muscle cancer	5.78e-05	0.000652	CcSEcCtD
Alitretinoin—Tinnitus—Doxorubicin—muscle cancer	5.77e-05	0.000651	CcSEcCtD
Alitretinoin—Anaemia—Methotrexate—muscle cancer	5.75e-05	0.000649	CcSEcCtD
Alitretinoin—Flushing—Doxorubicin—muscle cancer	5.75e-05	0.000648	CcSEcCtD
Alitretinoin—Angiopathy—Doxorubicin—muscle cancer	5.62e-05	0.000634	CcSEcCtD
Alitretinoin—Malaise—Methotrexate—muscle cancer	5.61e-05	0.000633	CcSEcCtD
Alitretinoin—Dizziness—Etoposide—muscle cancer	5.61e-05	0.000633	CcSEcCtD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—MED12—muscle cancer	5.6e-05	0.00295	CbGpPWpGaD
Alitretinoin—Chills—Doxorubicin—muscle cancer	5.56e-05	0.000627	CcSEcCtD
Alitretinoin—Arrhythmia—Doxorubicin—muscle cancer	5.53e-05	0.000624	CcSEcCtD
Alitretinoin—Alopecia—Doxorubicin—muscle cancer	5.47e-05	0.000617	CcSEcCtD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	5.44e-05	0.00287	CbGpPWpGaD
Alitretinoin—Cough—Methotrexate—muscle cancer	5.43e-05	0.000613	CcSEcCtD
Alitretinoin—Mental disorder—Doxorubicin—muscle cancer	5.42e-05	0.000612	CcSEcCtD
Alitretinoin—Convulsion—Methotrexate—muscle cancer	5.39e-05	0.000608	CcSEcCtD
Alitretinoin—Vomiting—Etoposide—muscle cancer	5.39e-05	0.000608	CcSEcCtD
Alitretinoin—Erythema—Doxorubicin—muscle cancer	5.39e-05	0.000608	CcSEcCtD
Alitretinoin—Malnutrition—Doxorubicin—muscle cancer	5.39e-05	0.000608	CcSEcCtD
Alitretinoin—Rash—Etoposide—muscle cancer	5.35e-05	0.000603	CcSEcCtD
Alitretinoin—Dermatitis—Etoposide—muscle cancer	5.34e-05	0.000603	CcSEcCtD
Alitretinoin—Headache—Etoposide—muscle cancer	5.31e-05	0.000599	CcSEcCtD
Alitretinoin—Flatulence—Doxorubicin—muscle cancer	5.31e-05	0.000599	CcSEcCtD
Alitretinoin—Chest pain—Methotrexate—muscle cancer	5.3e-05	0.000598	CcSEcCtD
Alitretinoin—Arthralgia—Methotrexate—muscle cancer	5.3e-05	0.000598	CcSEcCtD
Alitretinoin—Myalgia—Methotrexate—muscle cancer	5.3e-05	0.000598	CcSEcCtD
Alitretinoin—Tension—Doxorubicin—muscle cancer	5.29e-05	0.000597	CcSEcCtD
Alitretinoin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	5.26e-05	0.000594	CcSEcCtD
Alitretinoin—Discomfort—Methotrexate—muscle cancer	5.24e-05	0.000591	CcSEcCtD
Alitretinoin—Nervousness—Doxorubicin—muscle cancer	5.23e-05	0.000591	CcSEcCtD
Alitretinoin—Back pain—Doxorubicin—muscle cancer	5.21e-05	0.000588	CcSEcCtD
Alitretinoin—Confusional state—Methotrexate—muscle cancer	5.12e-05	0.000578	CcSEcCtD
Alitretinoin—Anaphylactic shock—Methotrexate—muscle cancer	5.08e-05	0.000573	CcSEcCtD
Alitretinoin—Vision blurred—Doxorubicin—muscle cancer	5.08e-05	0.000573	CcSEcCtD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	5.07e-05	0.00267	CbGpPWpGaD
Alitretinoin—Infection—Methotrexate—muscle cancer	5.05e-05	0.000569	CcSEcCtD
Alitretinoin—Nausea—Etoposide—muscle cancer	5.04e-05	0.000568	CcSEcCtD
Alitretinoin—Ill-defined disorder—Doxorubicin—muscle cancer	5e-05	0.000564	CcSEcCtD
Alitretinoin—Nervous system disorder—Methotrexate—muscle cancer	4.98e-05	0.000562	CcSEcCtD
Alitretinoin—Anaemia—Doxorubicin—muscle cancer	4.98e-05	0.000562	CcSEcCtD
Alitretinoin—Thrombocytopenia—Methotrexate—muscle cancer	4.97e-05	0.000561	CcSEcCtD
Alitretinoin—Agitation—Doxorubicin—muscle cancer	4.95e-05	0.000559	CcSEcCtD
Alitretinoin—Skin disorder—Methotrexate—muscle cancer	4.93e-05	0.000557	CcSEcCtD
Alitretinoin—Hyperhidrosis—Methotrexate—muscle cancer	4.91e-05	0.000554	CcSEcCtD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	4.86e-05	0.00256	CbGpPWpGaD
Alitretinoin—Malaise—Doxorubicin—muscle cancer	4.86e-05	0.000548	CcSEcCtD
Alitretinoin—Anorexia—Methotrexate—muscle cancer	4.84e-05	0.000546	CcSEcCtD
Alitretinoin—Syncope—Doxorubicin—muscle cancer	4.83e-05	0.000545	CcSEcCtD
Alitretinoin—Palpitations—Doxorubicin—muscle cancer	4.76e-05	0.000537	CcSEcCtD
Alitretinoin—Hypotension—Methotrexate—muscle cancer	4.75e-05	0.000536	CcSEcCtD
Alitretinoin—Loss of consciousness—Doxorubicin—muscle cancer	4.74e-05	0.000534	CcSEcCtD
Alitretinoin—Cough—Doxorubicin—muscle cancer	4.7e-05	0.000531	CcSEcCtD
Alitretinoin—Convulsion—Doxorubicin—muscle cancer	4.67e-05	0.000527	CcSEcCtD
Alitretinoin—Hypertension—Doxorubicin—muscle cancer	4.65e-05	0.000525	CcSEcCtD
Alitretinoin—Musculoskeletal discomfort—Methotrexate—muscle cancer	4.63e-05	0.000522	CcSEcCtD
Alitretinoin—Insomnia—Methotrexate—muscle cancer	4.59e-05	0.000518	CcSEcCtD
Alitretinoin—Myalgia—Doxorubicin—muscle cancer	4.59e-05	0.000518	CcSEcCtD
Alitretinoin—Arthralgia—Doxorubicin—muscle cancer	4.59e-05	0.000518	CcSEcCtD
Alitretinoin—Chest pain—Doxorubicin—muscle cancer	4.59e-05	0.000518	CcSEcCtD
Alitretinoin—Anxiety—Doxorubicin—muscle cancer	4.57e-05	0.000516	CcSEcCtD
Alitretinoin—Paraesthesia—Methotrexate—muscle cancer	4.56e-05	0.000515	CcSEcCtD
Alitretinoin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	4.56e-05	0.000514	CcSEcCtD
Alitretinoin—Discomfort—Doxorubicin—muscle cancer	4.53e-05	0.000511	CcSEcCtD
Alitretinoin—Dyspnoea—Methotrexate—muscle cancer	4.53e-05	0.000511	CcSEcCtD
Alitretinoin—Somnolence—Methotrexate—muscle cancer	4.52e-05	0.000509	CcSEcCtD
Alitretinoin—Dry mouth—Doxorubicin—muscle cancer	4.49e-05	0.000506	CcSEcCtD
Alitretinoin—Dyspepsia—Methotrexate—muscle cancer	4.47e-05	0.000504	CcSEcCtD
Alitretinoin—Confusional state—Doxorubicin—muscle cancer	4.44e-05	0.0005	CcSEcCtD
Alitretinoin—Decreased appetite—Methotrexate—muscle cancer	4.42e-05	0.000498	CcSEcCtD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	4.42e-05	0.00232	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—FH—muscle cancer	4.41e-05	0.00232	CbGpPWpGaD
Alitretinoin—CYP1A2—Tryptophan metabolism—MDM2—muscle cancer	4.4e-05	0.00232	CbGpPWpGaD
Alitretinoin—Oedema—Doxorubicin—muscle cancer	4.4e-05	0.000496	CcSEcCtD
Alitretinoin—Anaphylactic shock—Doxorubicin—muscle cancer	4.4e-05	0.000496	CcSEcCtD
Alitretinoin—Gastrointestinal disorder—Methotrexate—muscle cancer	4.39e-05	0.000495	CcSEcCtD
Alitretinoin—Fatigue—Methotrexate—muscle cancer	4.38e-05	0.000494	CcSEcCtD
Alitretinoin—Infection—Doxorubicin—muscle cancer	4.37e-05	0.000493	CcSEcCtD
Alitretinoin—Pain—Methotrexate—muscle cancer	4.34e-05	0.00049	CcSEcCtD
Alitretinoin—Shock—Doxorubicin—muscle cancer	4.33e-05	0.000488	CcSEcCtD
Alitretinoin—Nervous system disorder—Doxorubicin—muscle cancer	4.31e-05	0.000487	CcSEcCtD
Alitretinoin—Thrombocytopenia—Doxorubicin—muscle cancer	4.31e-05	0.000486	CcSEcCtD
Alitretinoin—Tachycardia—Doxorubicin—muscle cancer	4.29e-05	0.000484	CcSEcCtD
Alitretinoin—Skin disorder—Doxorubicin—muscle cancer	4.27e-05	0.000482	CcSEcCtD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	4.26e-05	0.00224	CbGpPWpGaD
Alitretinoin—Hyperhidrosis—Doxorubicin—muscle cancer	4.25e-05	0.00048	CcSEcCtD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—muscle cancer	4.24e-05	0.00223	CbGpPWpGaD
Alitretinoin—Anorexia—Doxorubicin—muscle cancer	4.19e-05	0.000473	CcSEcCtD
Alitretinoin—Feeling abnormal—Methotrexate—muscle cancer	4.19e-05	0.000472	CcSEcCtD
Alitretinoin—Gastrointestinal pain—Methotrexate—muscle cancer	4.15e-05	0.000469	CcSEcCtD
Alitretinoin—Hypotension—Doxorubicin—muscle cancer	4.11e-05	0.000464	CcSEcCtD
Alitretinoin—Urticaria—Methotrexate—muscle cancer	4.04e-05	0.000455	CcSEcCtD
Alitretinoin—Body temperature increased—Methotrexate—muscle cancer	4.02e-05	0.000453	CcSEcCtD
Alitretinoin—Abdominal pain—Methotrexate—muscle cancer	4.02e-05	0.000453	CcSEcCtD
Alitretinoin—Musculoskeletal discomfort—Doxorubicin—muscle cancer	4.01e-05	0.000452	CcSEcCtD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	3.98e-05	0.0021	CbGpPWpGaD
Alitretinoin—Insomnia—Doxorubicin—muscle cancer	3.98e-05	0.000449	CcSEcCtD
Alitretinoin—CYP1A2—Arachidonic acid metabolism—PTGS2—muscle cancer	3.97e-05	0.00209	CbGpPWpGaD
Alitretinoin—Paraesthesia—Doxorubicin—muscle cancer	3.95e-05	0.000446	CcSEcCtD
Alitretinoin—Dyspnoea—Doxorubicin—muscle cancer	3.92e-05	0.000442	CcSEcCtD
Alitretinoin—Somnolence—Doxorubicin—muscle cancer	3.91e-05	0.000441	CcSEcCtD
Alitretinoin—Dyspepsia—Doxorubicin—muscle cancer	3.87e-05	0.000437	CcSEcCtD
Alitretinoin—Decreased appetite—Doxorubicin—muscle cancer	3.82e-05	0.000431	CcSEcCtD
Alitretinoin—Gastrointestinal disorder—Doxorubicin—muscle cancer	3.8e-05	0.000428	CcSEcCtD
Alitretinoin—Fatigue—Doxorubicin—muscle cancer	3.79e-05	0.000428	CcSEcCtD
Alitretinoin—Constipation—Doxorubicin—muscle cancer	3.76e-05	0.000424	CcSEcCtD
Alitretinoin—Pain—Doxorubicin—muscle cancer	3.76e-05	0.000424	CcSEcCtD
Alitretinoin—Hypersensitivity—Methotrexate—muscle cancer	3.74e-05	0.000422	CcSEcCtD
Alitretinoin—Asthenia—Methotrexate—muscle cancer	3.64e-05	0.000411	CcSEcCtD
Alitretinoin—Feeling abnormal—Doxorubicin—muscle cancer	3.62e-05	0.000409	CcSEcCtD
Alitretinoin—Gastrointestinal pain—Doxorubicin—muscle cancer	3.6e-05	0.000406	CcSEcCtD
Alitretinoin—Pruritus—Methotrexate—muscle cancer	3.59e-05	0.000405	CcSEcCtD
Alitretinoin—Urticaria—Doxorubicin—muscle cancer	3.49e-05	0.000394	CcSEcCtD
Alitretinoin—Body temperature increased—Doxorubicin—muscle cancer	3.48e-05	0.000392	CcSEcCtD
Alitretinoin—Abdominal pain—Doxorubicin—muscle cancer	3.48e-05	0.000392	CcSEcCtD
Alitretinoin—Diarrhoea—Methotrexate—muscle cancer	3.48e-05	0.000392	CcSEcCtD
Alitretinoin—RXRA—Developmental Biology—FOXO1—muscle cancer	3.44e-05	0.00181	CbGpPWpGaD
Alitretinoin—Dizziness—Methotrexate—muscle cancer	3.36e-05	0.000379	CcSEcCtD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	3.35e-05	0.00176	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	3.34e-05	0.00176	CbGpPWpGaD
Alitretinoin—Hypersensitivity—Doxorubicin—muscle cancer	3.24e-05	0.000366	CcSEcCtD
Alitretinoin—Vomiting—Methotrexate—muscle cancer	3.23e-05	0.000364	CcSEcCtD
Alitretinoin—RXRA—Gene Expression—MED12—muscle cancer	3.21e-05	0.00169	CbGpPWpGaD
Alitretinoin—Rash—Methotrexate—muscle cancer	3.2e-05	0.000361	CcSEcCtD
Alitretinoin—Dermatitis—Methotrexate—muscle cancer	3.2e-05	0.000361	CcSEcCtD
Alitretinoin—Headache—Methotrexate—muscle cancer	3.18e-05	0.000359	CcSEcCtD
Alitretinoin—Asthenia—Doxorubicin—muscle cancer	3.16e-05	0.000356	CcSEcCtD
Alitretinoin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	3.14e-05	0.00165	CbGpPWpGaD
Alitretinoin—Pruritus—Doxorubicin—muscle cancer	3.11e-05	0.000351	CcSEcCtD
Alitretinoin—Nausea—Methotrexate—muscle cancer	3.02e-05	0.00034	CcSEcCtD
Alitretinoin—Diarrhoea—Doxorubicin—muscle cancer	3.01e-05	0.00034	CcSEcCtD
Alitretinoin—Dizziness—Doxorubicin—muscle cancer	2.91e-05	0.000328	CcSEcCtD
Alitretinoin—Vomiting—Doxorubicin—muscle cancer	2.8e-05	0.000316	CcSEcCtD
Alitretinoin—Rash—Doxorubicin—muscle cancer	2.77e-05	0.000313	CcSEcCtD
Alitretinoin—Dermatitis—Doxorubicin—muscle cancer	2.77e-05	0.000313	CcSEcCtD
Alitretinoin—Headache—Doxorubicin—muscle cancer	2.76e-05	0.000311	CcSEcCtD
Alitretinoin—ABCB1—Allograft Rejection—VEGFA—muscle cancer	2.72e-05	0.00143	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—PTGS2—muscle cancer	2.61e-05	0.00138	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—PTGS2—muscle cancer	2.61e-05	0.00138	CbGpPWpGaD
Alitretinoin—Nausea—Doxorubicin—muscle cancer	2.61e-05	0.000295	CcSEcCtD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	2.53e-05	0.00133	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—MED12—muscle cancer	2.49e-05	0.00131	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—ENO2—muscle cancer	2.27e-05	0.0012	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—MED12—muscle cancer	1.79e-05	0.00094	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.78e-05	0.000935	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	1.76e-05	0.000928	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—FH—muscle cancer	1.76e-05	0.000928	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	1.7e-05	0.000895	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—VEGFA—muscle cancer	1.57e-05	0.000825	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—FH—muscle cancer	1.41e-05	0.000741	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	1.34e-05	0.000705	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	1.01e-05	0.000533	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—MED12—muscle cancer	9.96e-06	0.000524	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—ENO2—muscle cancer	9.08e-06	0.000478	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—MED12—muscle cancer	7.95e-06	0.000418	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—PTGS2—muscle cancer	7.92e-06	0.000417	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—ENO2—muscle cancer	7.25e-06	0.000382	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	5.67e-06	0.000298	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—PTGS2—muscle cancer	3.16e-06	0.000166	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—PTGS2—muscle cancer	2.53e-06	0.000133	CbGpPWpGaD
